About the Epilepsy Drugs Market Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology. Etiology Etiology varies according to the age of a person. Some individuals genetically inherit the disease while the cause of the disease in others is unknown. Head injuries, tumors, autism spectrum disorder, or stroke can also cause the disorder. Technavio's analysts forecast the global epilepsy drugs market to grow at a CAGR of 4.45% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global epilepsy drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent epilepsy and related seizures. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Epilepsy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors Eisai GSK Pfizer UCB Other prominent vendors AbbVie Acorda Therapeutics Alexza Pharmaceuticals Aprecia Pharmaceuticals Aurobindo Pharma Biscayne Pharmaceuticals CURx Pharmaceuticals Dainippon Sumitomo Pharma D-Pharm F. Hoffmann-La Roche Grupo Ferrer Internacional GW Pharmaceuticals Insero Health INSYS Therapeutics Janssen Pharmaceuticals Ligand Pharmaceuticals H. Lundbeck MarcoPolo Pharmaceuticals Marinus Pharmaceuticals Meda Neurelis Nobelpharma Novartis Orphelia Pharma SAGE Therapeutics SciFlour Sedor Pharmaceuticals Shire SK Biopharmaceuticals Sun Pharmaceutical Sunovion Pharmaceuticals (US) Supernus Pharmaceuticals Takeda Turing Pharmaceuticals Upsher-Smith Valeant Pharmaceutical Zogenix Market driver Tentative approval of late-stage pipeline molecules For a full, detailed list, view our report Market challenge Social stigma associated with epilepsy For a full, detailed list, view our report Market trend Reformulation of marketed drugs For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary Highlights PART 02: Scope of the report Market overview Top-vendor offerings PART 03: Market research methodology Research methodology Economic indicators PART 04: Introduction Key market highlights Epilepsy: An overview PART 05: Pipeline analysis PART 06: Key buying criteria for anti-epileptic drugs PART 07: Market landscape Market overview Five forces analysis PART 08: Market segmentation by generation of drugs First-generation anti-epileptic drugs Second-generation anti-epileptic drugs Third-generation anti-epileptic drugs PART 09: Market segmentation by spectrum of activity Narrow-spectrum anti-epileptic drugs Broad-spectrum anti-epileptic drugs PART 10: Market segmentation by type of seizures Partial onset seizures Generalized seizures PART 11: Geographical segmentation Global epilepsy drugs market by geography 2016-2020 Epilepsy drugs market in Americas Epilepsy drugs market in US Epilepsy drugs market in EMEA Epilepsy drugs market in APAC Epilepsy drugs market in Japan Epilepsy drugs market in Australia Epilepsy drugs market in China Epilepsy drugs market in India PART 12: Market drivers Tentative approval of late-stage pipeline molecules Special regulatory designations Development of novel therapeutics using innovative technologies PART 13: Impact of drivers PART 14: Market challenges Social stigma associated with epilepsy Growing use of seizure management devices is a threat to drug therapies Gradual decrease in incentives/investment by vendors for new drug development PART 15: Impact of drivers and challenges PART 16: Market trends Development of devices and smartphone apps to detect seizures and track medications Reformulation of marketed drugs Increased uptake of new-generation drugs PART 17: Vendor landscape Competitive scenario Key news PART 18: Key vendor analysis Eisai GSK Pfizer UCB Other prominent vendors PART 19: Appendix List of abbreviations PART 20: Explore Technavio List of Exhibits
Exhibit 01: Product offerings Exhibit 02: Pipeline portfolio: Epilepsy drugs Exhibit 03: Percentage share of pipeline molecules for global epilepsy drugs market Exhibit 04: Key buying criteria for anti-epileptic drugs Exhibit 05: Global epilepsy drugs market snapshot: Developed and emerging markets 2015 Exhibit 06: Global epilepsy drugs market 2015-2020 ($ billions) Exhibit 07: A few research studies targeting cause of epilepsy Exhibit 08: Segmentation of marketed anti-epileptic drugs based on mechanism of action Exhibit 09: Five forces analysis Exhibit 10: Timeline of development of anti-epileptic drugs Exhibit 11: Segmentation of global anti-epileptic drugs market based on generation of drugs 2015 Exhibit 12: Opportunity analysis of global epilepsy drugs market by generation of drugs Exhibit 13: Segmentation of global epilepsy drugs market by the spectrum of activity of drugs 2015 Exhibit 14: Segmentation of global epilepsy drugs market based on type of seizures Exhibit 15: Global epilepsy drugs market by geography 2015-2020 Exhibit 16: Global epilepsy drugs market by geography 2015 and 2020 Exhibit 17: Global epilepsy drugs market by geography 2015-2020 ($ billions) Exhibit 18: Epilepsy drugs market in Americas 2015-2020 ($ billions) Exhibit 19: Epilepsy drugs market in Americas by geography 2015 Exhibit 20: Comparison of US healthcare system: Before and after reforms Exhibit 21: Epilepsy drugs market in US 2015-2020 ($ billions) Exhibit 22: Epilepsy drugs market in EMEA by geography 2015 Exhibit 23: Epilepsy drugs market in EMEA 2015-2020 ($ billions) Exhibit 24: Epilepsy drugs market in APAC 2015-2020 ($ billions) Exhibit 25: Epilepsy drugs market in APAC by geography 2015 Exhibit 26: Epilepsy drugs market in Japan 2015-2020 ($ millions) Exhibit 27: Epilepsy drugs market in Australia 2015-2020 ($ millions) Exhibit 28: Epilepsy drugs market in China 2015-2020 ($ millions) Exhibit 29: Epilepsy drugs market in India 2015-2020 ($ millions) Exhibit 30: Impact of drivers Exhibit 31: Impact of drivers and challenges Exhibit 32: Position of key vendors in global epilepsy drugs market 2015 Exhibit 33: Geographical presence of key vendors Exhibit 34: Company portfolio analysis in global epilepsy drugs market 2016-2020 Exhibit 35: Eisai: YoY revenue and growth rate of Fycompa (Americas and EMEA) 2013-2015 ($ millions) Exhibit 36: Eisai: YoY revenue and growth rate of Zonegran (EMEA) 2013-2015 ($ millions) Exhibit 37: Eisai: YoY revenue and growth rate of Banzel (Americas and EMEA) 2013-2015 ($ millions) Exhibit 38: Eisai: YoY revenue and growth rate of Zebinix (EMEA) 2013-2015 ($ millions) Exhibit 39: Eisai: Metrics analysis Exhibit 40: GSK: YoY revenue and growth rate of Lamictal 2013-2015 ($ millions) Exhibit 41: GSK: Metrics analysis Exhibit 42: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions) Exhibit 43: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions) Exhibit 44: Pfizer: Metrics analysis Exhibit 45: UCB: YoY revenue and growth rate of Keppra 2013-2015 ($ millions) Exhibit 46: UCB: Geographical segmentation of Keppra by revenue 2015 Exhibit 47: UCB: YoY revenue and growth rate of Vimpat 2013-2015 ($ millions) Exhibit 48: UCB: Geographical segmentation of Keppra by revenue 2015 Exhibit 49: UCB: Metrics analysis
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.